A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study - Burtness, B A; Manola, J; Axelrod, R (Ann Oncol, 2008)
et al.